Imbalance of Oxidants and Antioxidants in Haemodialysis Patients (original) (raw)

Abstract

Dialysis-related pathology (DRP) observed in long-term haemodialysis patients is increasingly reported. Among DRP manifestations, cardiovascular disease is the most frequent, being the first cause of mortality in haemodialysis patients. Alterations in lipid metabolism and oxidative stress are recognised as major risk factors that could be prevented or reduced by optimal therapy.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (54)

  1. London GM, Drueke TB: Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997;51:1678-1695.
  2. Jadoul M: Dialysis-related amyloidosis: Impor- tance of biocompatibility and age. Nephrol Dial Transplant 1998;7:61-64.
  3. London GM, Parfrey PS: Cardiac disease in chronic uremia: Pathogenesis. Adv Ren Re- place Ther 1997;4:194-211.
  4. Becker BN, Himmelfarb J, Henrich WL, Ha- kim RM: Reassessing the cardiac risk profile in chronic haemodialysis patients: A hypothesis on the role of oxidant stress and other non-tra- ditional cardiac risk factors. J Am Soc Nephrol 1997;8:475-486.
  5. Schaefer RM, Gilge U, Goehl H, Heidland A: Evaluation of a new polyamide membrane (Polyflux 130) in high-flux dialysis. Blood Purif 1990;8:23-31.
  6. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K et al: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51:1170-1181.
  7. van Ypersele de Strihou C: Are biocompatible membranes superior for haemodialysis thera- py? Kidney Int Suppl 1997;62:S101-S104.
  8. Ehlerding G, Schaeffer J, Drommer W, Miyata T, Koch KM, Floege J: Alterations of synovial tissue and their potential role in the deposition of beta2-microglobulin-associated amyloid. Nephrol Dial Transplant 1998;13:1465-1475.
  9. 9 Le Meur Y, Fixe P, Aldigier JC, Leroux-Robert C, Praloran V: Macrophage colony stimulating factor involvement in uremic patients. Kidney Int 1996;50:1007-1012.
  10. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Ver- ger C et al: Balance between IL-1 beta, TNF- alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Rela- tionships with activation markers of T cells, B cells, and monocytes. J Immunol 1995;154: 882-892.
  11. Bergstrom J, Wang T, Lindholm B: Factors contributing to catabolism in end-stage renal disease patients. Miner Electrolyte Metab 1998;24:92-101.
  12. Dwyer JT, Cunniff PJ, Maroni BJ, Kopple JD, Burrowes JD, Powers SN, Cockram DB et al: The haemodialysis pilot study: Nutrition pro- gram and participant characteristics at base- line. The HEMO Study Group. J Ren Nutr 1998;8:11-20.
  13. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A et al: Enhanced LDL oxidation in uremic patients: An addi- tional mechanism for accelerated atherosclero- sis? Kidney Int 1994;45:876-833.
  14. Fiorillo C, Oliviero C, Rizzuti G, Nediani C, Pacini A, Nassi P: Oxidative stress and antioxi- dant defenses in renal patients receiving regu- lar haemodialysis. Clin Chem Lab Med 1998; 36:149-153.
  15. Biasioli S, Schiavon R, Petrosino L, Cavallini L, Zambello A, De Fanti E, Giavarina D: Free radicals and oxidative stress challenge dialysis patients: Effects of two different membranes. ASAIO J 1997;43:M766-M772.
  16. Hasselwander O, Young IS: Oxidative stress in chronic renal failure. Free Radic Res 1998;29: 1-11.
  17. Ward RA, McLesh KR: Polymorphonuclear leukocyte oxidative burst is enhanced in pa- tients with chronic renal insufficiency. J Am Soc Nephrol 1994;5:1697-1702.
  18. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxi- dative stress in haemodialysis. QJM 1994;87: 679-683.
  19. Koenig JS, Fischer M, Bulant E, Tiran B, Elmadfa I, Druml W: Antioxidant status in patients on chronic haemodialysis therapy: Im- pact of parenteral selenium supplementation. Wien Klin Wochenschr 1997;109:13-19.
  20. Blood Purif 1999;17:99-106
  21. Steinberg D, Parthasarthy S, Carew TE, Khoo JC, Witzum JL: Beyond cholesterol: Modifica- tions of low density lipoproteins that its in- crease its atherogenicity. N Engl J Med 1989; 320:915-924.
  22. Esterbauer H, Gebicki J, Pulh H, Jurgen G: The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Bio Med 1992;13:341-390.
  23. Diaz MN, Frei B, Vita JA, Keaney JF: Antioxi- dants and atherosclerotic heart disease. N Engl J Med 1997;337:408-416.
  24. Ross R: Atherogenesis; in Gallin JI, Goldstein IM, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates. New York, Raven Press, 1992, pp 1051-1059.
  25. Witko-Sarsat V, Friedlander M, Capeillere- Blandin C, Nguyen-Khoa T, Nguyen AT, Zin- graff J, Jungers P et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304- 1313.
  26. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Cante- loup S, Dayer JM et al: Advanced oxidation protein products as novel mediators of inflam- mation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-2532.
  27. Keaney JF, Loscalzo J: Diabetes, oxidative stress, and platelet activation. Circulation 1999;99:189-191.
  28. Hayoz D, Ziegler T, Brunner HR, Ruiz J: Dia- betes mellitus and vascular lesions. Metabo- lism 1998;47:16-19.
  29. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: A new per- spective an old paradigm. Diabetes 1999;48:1- 9.
  30. Casino FG, Lopez T: The equivalent renal urea clearance: A new parameter to assess dialysis dose. Nephrol Dial Transplant 1996;11:1574- 1581.
  31. Morena M, Cristol JP, Bosc JY, Tetta C, Forret G, Descomps B, Canaud B: Convective and diffusive losses of vitamin C during hemodia- filtration session: A contributive factor to oxi- dative stress in haemodialysis patients. Ne- phrol Dial Transplant 1998;13.
  32. Ward RA, McLeish KR: Hemodialysis with cellulose membranes primes the neutrophil ox- idative burst. Artif Organs 1995;19:801-807.
  33. Cristol JP, Canaud B, Rabesandratana H, Gail- lard I, Serre A, Mion C: Enhancement of reac- tive oxygen species production and cell surface markers expression due to haemodialysis. Nephrol Dial Transplant 1994;9:389-394.
  34. Dinarello CA, Lonnemann G, Bingel M, Koch KM, Shaldon S: Biological consequences of monocyte activation during haemodialysis. Contrib Nephrol 1987;59:1-9.
  35. Lonnemann G, Haubitz M, Schindler R: He- modialysis-associated induction of cytokines. Blood Purif 1990;8:214-222.
  36. Haubitz M, Kloppel B, Lonnemann G, Non- nast-Daniel B: In vitro production of interleu- kin-1 from blood mononuclear cells of patients on chronic haemodialysis therapy. Clin Ne- phrol 1992;38:30-35.
  37. Knudsen PJ, Leon J, Ng AK, Shaldon S, Floege J, Koch KM: Hemodialysis-related induction of beta-2-microglobulin and interleukin-1 syn- thesis and release by mononuclear phagocytes. Nephron 1989;53:188-193.
  38. Knudsen PJ, Shaldon S, Floege J, Koch M: Hemodialysis-related induction of beta 2-mi- croglobulin synthesis and release by mononu- clear phagocytes. Int J Artif Organs 1990;13: 73-76.
  39. Nockher WA, Scherberich JE: Monocyte cell- surface CD14 expression and soluble CD14 antigen in haemodialysis: Evidence for chronic exposure to LPS. Kidney Int 1995;48:1469- 1476.
  40. DeLeo FR, Renee J, McCormick S, Nakamura M, Apicella M, Weiss JP, Nauseef WM: Neu- trophils exposed to bacterial lipopolysaccha- ride upregulate NADPH oxidase assembly. J Clin Invest 1998;101:455-463.
  41. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C, Clerc M: Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: Vita- mins A, E, and iron status. Free Radic Biol Med 1994;16:339-346.
  42. Haber F, Weiss J: The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc Lond A 1934;147:332-351.
  43. Halliwell B: Free radicals and antioxidants: A personal view. Nutrition Reviews 1994;52: 253-265.
  44. Sommerburg O, Grune T, Hampl H, Riedel E, van Kuijk FJ, Ehrich JH, Siems WG: Does long-term treatment of renal anaemia with re- combinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 1998;13:2583-2587.
  45. Chen HC, Tsai JC, Tsai JH, Lai YH: Recombi- nant human erythropoietin enhances superox- ide production by FMLP-stimulated polymor- phonuclear leukocytes in haemodialysis pa- tients. Kidney Int 1997;52:1390-1394.
  46. Canaud B, Bosc JY, Leray H, Stec F, Argiles A, Leblanc M, Mion C: On-line haemodiafiltra- tion: State of the art. Nephrol Dial Transplant 1998;5:3-11.
  47. Stephens NG, Parsons A, Schofield PM, Kelly F, Mitchinson MJ: Randomised controlled trial of vitamin E in patients with coronary dis- ease: Cambridge Heart Antioxidant Study. Lancet 1996;347:781-786.
  48. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B, Canaud B: Erythropoi- etin and oxidative stress in haemodialysis: Ben- eficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997;12:2312-2317.
  49. Hussein O, Rosenblat M, Refael G, Aviram M: Dietary selenium increases cellular glutathione peroxidase activity and reduces the enhanced susceptibility to lipid peroxidation of plasma and low-density lipoprotein in kidney trans- plant recipients. Transplantation 1997;63: 679-685.
  50. Buoncristiani U, Galli F, Rovidati S, Albertini MC, Campus G, Canestrari F: Oxidative dam- age during haemodialysis using a vitamin-E- modified dialysis membrane: A preliminary characterization. Nephron 1997;77:57-61.
  51. Galli F, Rovidati S, Chiarantini L, Campus G, Canestrari F, Buoncristiani U: Bioreactivity and biocompatibility of a vitamin E-modified multilayer haemodialysis filter. Kidney Int 1998;54:580-589.
  52. Wratten ML, Sereni L, Tropea F, Tetta C: Hemolipodialysis removes hydrophobic toxins and reduces oxidative stress in an in vitro mod- el system. Nephrol Dial Transplant 1998;13: A184.
  53. Ziouzenkova O, Wratten ML, Tetta C, Sevan- ian A: Antioxidants delivered by liposomes de- crease the oxidative modifications of LDL and haemodialysis during extracorporeal blood cir- culation. Nephrol Dial Transplant 1998;13: A121.
  54. Tetta C, Wratten ML, Cristol JP, Tarchini R, Bosc JY, Canaud B, Camussi G: The role of platelet-activating factor in the haemocompati- bility of haemodialytic treatments. Int J Artif Organs 1998;21:693-698.